BACKGROUND Experimental, clinical, and epidemiological studies have implicated mitogenic metabolites of arachidonic acid such as prostaglandin E2(PGE2) in colorectal carcinogenesis. Recently, cyclooxygenase 2 (COX-2) which catalyses the conversion of arachidonic acid to PGE2, has displayed increased levels in human colorectal cancer.
AIMS To evaluate whether there is differential COX-2 expression from different locations (caecum, ascending, transverse, descending, or sigmoid colon, and rectum) in human colorectal cancer.
METHODS Protein levels of COX-2 were determined by western blot analysis in tumours and adjacent normal mucosa of 39 patients with colorectal cancer.
RESULTS There was a notable overexpression of COX-2 protein in tumours located in the rectum (p<0.001) compared with other locations in the colon. Rectal tumours revealed elevated COX-2 protein levels in 18/20 cases compared with 4/19 colonic cases. No association between enhanced COX-2 protein expression in tumour tissue and Dukes’s stages was found.
CONCLUSIONS Results suggest that the differential COX-2 expression may be due to differences in gene regulatory factors affecting COX-2 expression and/or reflect secondary changes in tumour progression which may have clinical implications.
- cyclooxygenase 2
- protein expression
- human colorectal cancer
Statistics from Altmetric.com
- Abbreviations used in this paper:
- adenomatous polyposis coli
- cytosolic phospholipase A2
- non-steroidal anti-inflammatory drug
- prostaglandin E2
- group II phospholipase A2
- peroxisome proliferator activated receptor
- T cell factor/leucocyte enhancing factor
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.